Green algae shows potential for SBS

3 November 2008

A new study published in the World Journal of Gastroenterology suggests that a species of freshwater green algae may have benefits for people suffering from short bowel syndrome.

A team from the Turkish Gazi University Experimental Surgery Center found that a crude extract of the algae chlorella had a positive effect on rats with SBS. Dosing with the substance lead to a significant increase in intestinal villi height and width, intestinal protein and DNA amount and serum citruline levels, according to the study.

SBS is a clinical condition characterized by diarrhea, dehydration, electrolyte imbalance, malabsorption and progressive malnutrition related to a wide resection of the small intestine. The most important therapeutic objective of the disease, according to the study, is to maintain the patient's calorie and nutritional intake. Chlorella has been used in the Far East for hundreds of years as a food source and a traditional remedy.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight